Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Short Interest Update

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) was the recipient of a large decrease in short interest in the month of February. As of February 13th, there was short interest totaling 104,240 shares, a decrease of 59.8% from the January 29th total of 259,453 shares. Approximately 1.6% of the shares of the stock are sold short. Based on an average trading volume of 102,383 shares, the days-to-cover ratio is presently 1.0 days. Based on an average trading volume of 102,383 shares, the days-to-cover ratio is presently 1.0 days. Approximately 1.6% of the shares of the stock are sold short.

Calidi Biotherapeutics Price Performance

Shares of NYSEAMERICAN CLDI traded down $0.06 during mid-day trading on Friday, reaching $0.79. The company had a trading volume of 21,200 shares, compared to its average volume of 77,489. Calidi Biotherapeutics has a one year low of $0.72 and a one year high of $19.20. The business’s 50-day simple moving average is $1.02 and its 200 day simple moving average is $1.52. The company has a quick ratio of 2.12, a current ratio of 2.12 and a debt-to-equity ratio of 0.11.

Institutional Trading of Calidi Biotherapeutics

Large investors have recently made changes to their positions in the company. Warberg Asset Management LLC bought a new position in Calidi Biotherapeutics in the third quarter valued at approximately $28,000. Virtu Financial LLC acquired a new stake in shares of Calidi Biotherapeutics in the 4th quarter valued at $25,000. DRW Securities LLC bought a new position in shares of Calidi Biotherapeutics in the 4th quarter valued at $173,000. Finally, Geode Capital Management LLC raised its holdings in shares of Calidi Biotherapeutics by 41.7% during the 4th quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock worth $49,000 after buying an additional 12,334 shares in the last quarter. Institutional investors and hedge funds own 12.53% of the company’s stock.

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.